Article

OSI/Eyetech begins enrollment of DME clinical trial

OSI/Eyetech Pharmaceuticals Inc. (Melville, NY, and New York) began enrollment of a phase III trial to determine the safety and efficacy of pegaptanib sodium injection (Macugen) in patients with diabetic macular edema (DME). Patients will receive intravitreous injections of 0.3, 0.03, or 0.003 mg of pegaptanib sodium, or placebo injections, every 6 weeks for 3 years.

The randomized, controlled, double-masked, multicenter, and comparative dose-finding trial will use the diabetic retinopathy score as a pre-specified secondary endpoint. Enrollment is scheduled to conclude February 2007 and is anticipated to include 900 patients.

"In limited phase II studies, Macugen, the only anti-VEGF (vascular endothelial growth factor) therapy being studied in DME and diabetic retinopathy in large clinical trials, has shown potential in treating these conditions," said Michael Altaweel, MD, department of ophthalmology and visual sciences, University of Wisconsin, Madison.

The drug, a pegylated anti-VEGF aptamer that binds to VEGF, is indicated in the United States and Brazil for the treatment of neovascular age-related macular degeneration (AMD) and in Canada for the treatment of subfoveal choroidal neovascularization secondary to AMD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.